In a subset of patients in a 48-week extension trial, the mean duration of the first treatment-free interval was ...

A product doesn’t gain cult status overnight, and Sudocrem has the nappy rash healing credentials to back up its reputation.

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) has approved ...